267416-81-9

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
5-AMINO-2-(PHENOXY)BENZOTRIFLUORIDE is utilized as a building block in the synthesis of various pharmaceuticals and agrochemicals. Its unique chemical properties contribute to the development of new and effective compounds for these industries.
Used in Organic Synthesis:
As a reagent, 5-AMINO-2-(PHENOXY)BENZOTRIFLUORIDE is employed in organic synthesis, particularly for the preparation of heterocyclic compounds. Its strong electron-withdrawing nature facilitates a range of chemical reactions, making it a key component in the creation of complex organic molecules.
Used in the Field of Organic Chemistry:
5-AMINO-2-(PHENOXY)BENZOTRIFLUORIDE is recognized for its versatility in various chemical reactions within the field of organic chemistry. Its properties allow it to be a crucial element in advancing research and development in chemical synthesis and compound design.

InChI:InChI=1/C13H10F3NO/c14-13(15,16)11-8-9(17)6-7-12(11)18-10-4-2-1-3-5-10/h1-8H,17H2

Upstream product

• 6969-95-5 4-phenoxy3-trifluoromethylnitrobenzene 
• 108-95-2 phenol 
• 400-74-8 2-Fluoro-5-nitrobenzotrifluoride 

Relevant academic research and scientific papers

Structural Development of Salicylanilide-Based SPAK Inhibitors as Candidate Antihypertensive Agents

Hypertension is an important target for drug discovery. We have focused on the with-no-lysine kinase (WNK)-oxidative stress-responsive 1 (OSR1) and STE20/SPS1-related proline-alanine-rich protein kinase (SPAK)-NaCl cotransporter (NCC) signal cascade as a potential target, and we previously developed a screening system for inhibitors of WNK-OSR1/SPAK-NCC signaling. Herein we used this system to examine the structure-activity relationship (SAR) of salicylanilide derivatives as SPAK kinase inhibitors. Structural design and development based on our previous hit compound, aryloxybenzanilide derivative 2, and the veterinary anthelmintic closantel (3) led to the discovery of compound 10 a as a potent SPAK inhibitor with reduced toxicity. Compound 10 a decreased the phosphorylation level of NCC in mouse kidney in vivo, and appears to be a promising lead compound for a new class of antihypertensive drugs.

Structural development of N-(4-phenoxyphenyl)benzamide derivatives as novel SPAK inhibitors blocking WNK kinase signaling

We report here structural development of N-(4-phenoxyphenyl)benzamide derivatives as novel SPAK (STE20/SPS1-related proline/alanine-rich kinase) inhibitors. Abnormal activation of the signal cascade of with-no-lysine kinase (WNK) with OSR1 (oxidative stress-responsive kinase 1)/SPAK and NCC (NaCl cotransporter) results in characteristic salt-sensitive hypertension, and therefore inhibitors of the WNK-OSR1/SPAK-NCC cascade are candidates for antihypertensive drugs. Based on the structure of lead compound 2, we examined the SAR of N-(4-phenoxyphenyl)benzamide derivatives, and developed compound 20l as a potent SPAK inhibitor. Compounds 20l is a promising candidate for a new class of antihypertensive drugs.

Substituted bicyclic derivatives useful as anticancer agents

The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts and solvates thereof, wherein A, X, R1, R3and R4are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals with administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.